Efficacy of a synthetic lytic peptide in the treatment of prostate cancer

Urologic Oncology

Volumn 6, Issue 3, 2001, Pages 97-102

  Arlotti, Julie A ^a   Cimino, Tami S ^a   Nguyen, Thu Suong ^a   Dhir, Rajiv ^a   Thomas, Angela ^a   Jaynes, Jesse M ^b   Caldwell Jr , A Lee ^b   Getzenberg, Robert H ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Demegen Inc   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cancer; Cell membrane; Peptides; Prostate; Rat

Indexed keywords

D2A21; EOSIN; HEMATOXYLIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; LUNG METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RAT; TUMOR GROWTH; TUMOR VOLUME;

EID: 0035043234     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00120-4     Document Type: Article

References (6)

1. Peptide antibiotics and their role in innate immunity
2. In vitro cytocidal effect of lytic peptides on several transformed mammalian cell lines
3. Peptidyl membrane interactive molecules are cytotoxic to prostatic cancer cells in vitro
4. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancer